OVERVIEW
This 90-minute live symposium will feature 1 moderator and 2 panel members, all hematology/oncology specialists with expertise in myelofibrosis (MF). The program will begin with a didactic review of the treatment landscape, including the role of current and emerging Janus kinase (JAK) inhibitors in the MF treatment paradigm. An engaging series of patient cases and expert discussion will follow. Interspersed throughout the program will be “Do You Know JAK?" quiz questions” to engage the audience and ensure a lively and interactive session.
GOAL STATEMENT
The goal of this activity is for learners to improve their ability to diagnose and treat MF based on the latest data and the specific role of JAK inhibitors in the treatment paradigm. Through case-based learning, clinicians will be better equipped to tailor therapy for their patients and to manage adverse effects of treatment that may occur.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Clinical trial data on JAK inhibitor use in the treatment of MF [ITEM]JAK-STAT pathway and the mechanism of action of available JAK inhibitors[/LIST] Have greater competence related to [LIST] [ITEM]Stratifying risk for patients with MF [ITEM]Selecting appropriate therapy for patients with MF and cytopenias [ITEM]Managing adverse events of MF therapies[/LIST] Demonstrate greater confidence in their ability to [LIST] [ITEM]Individualize treatment for patients with MF[/LIST]
ACCREDITATION STATEMENT
[JALOGO][MEDSCAPE] In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hyatt Regency New Orleans
Empire B
601 Loyola Avenue
New Orleans, Louisiana, 70113
United States
Friday Satellite Symposium on Hematology/Oncology, Preceding the 64th ASH Annual Meeting and Exposition.
Supported by independent educational grants from [bold]Bristol Myers Squibb Company; and Sierra Oncology, a GSK company[/bold].